FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055033467> ?p ?o ?g. }

• W2055033467 endingPage "663" @default.
• W2055033467 startingPage "656" @default.
• W2055033467 abstract "Purpose To evaluate the feasibility, tolerance, and preliminary outcome of an open MRI-guided prostate partial-volume high-dose-rate brachytherapy (HDR-BT) schedule in a group of selected patients with nonmetastatic, locally aggressive prostatic tumors. Methods and Materials After conventional fractionated three-dimensional conformal external radiotherapy to 64–64.4 Gy, 77 patients with nonmetastatic, locally aggressive (e.g., perineural invasion and/or Gleason score 8–10) prostate cancer were treated from June 2000 to August 2004, with HDR-BT using temporary open MRI-guided 192Ir implants, to escalate the dose in the boost region. Nineteen, 21, and 37 patients were sequentially treated with 2 fractions of 6 Gy, 7 Gy, and 8 Gy each, respectively. Neoadjuvant androgen deprivation was given to 62 patients for 6–24 months. Acute and late toxicity were scored according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scoring system. Results All 77 patients completed treatment as planned. Only 2 patients presented with Grade ≥3 acute urinary toxicity. The 3-year probability of Grade ≥2 late urinary and low gastrointestinal toxicity–free survival was 91.4% ± 3.4% and 94.4% ± 2.7%, respectively. Rates of 3-year biochemical disease-free survival (bDFS) and disease-specific survival were 87.1% ± 4.1% and 100%, respectively. Conclusions Boosting a partial volume of the prostate with hypofractionated HDR-BT for aggressive prostate cancer was feasible and showed limited long-term toxicity, which compared favorably with other dose-escalation methods in the literature. Preliminary bDFS was encouraging if one considers the negatively selected population of high-risk patients in this study. To evaluate the feasibility, tolerance, and preliminary outcome of an open MRI-guided prostate partial-volume high-dose-rate brachytherapy (HDR-BT) schedule in a group of selected patients with nonmetastatic, locally aggressive prostatic tumors. After conventional fractionated three-dimensional conformal external radiotherapy to 64–64.4 Gy, 77 patients with nonmetastatic, locally aggressive (e.g., perineural invasion and/or Gleason score 8–10) prostate cancer were treated from June 2000 to August 2004, with HDR-BT using temporary open MRI-guided 192Ir implants, to escalate the dose in the boost region. Nineteen, 21, and 37 patients were sequentially treated with 2 fractions of 6 Gy, 7 Gy, and 8 Gy each, respectively. Neoadjuvant androgen deprivation was given to 62 patients for 6–24 months. Acute and late toxicity were scored according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scoring system. All 77 patients completed treatment as planned. Only 2 patients presented with Grade ≥3 acute urinary toxicity. The 3-year probability of Grade ≥2 late urinary and low gastrointestinal toxicity–free survival was 91.4% ± 3.4% and 94.4% ± 2.7%, respectively. Rates of 3-year biochemical disease-free survival (bDFS) and disease-specific survival were 87.1% ± 4.1% and 100%, respectively. Boosting a partial volume of the prostate with hypofractionated HDR-BT for aggressive prostate cancer was feasible and showed limited long-term toxicity, which compared favorably with other dose-escalation methods in the literature. Preliminary bDFS was encouraging if one considers the negatively selected population of high-risk patients in this study." @default.
• W2055033467 created "2016-06-24" @default.
• W2055033467 creator A5006149096 @default.
• W2055033467 creator A5015539696 @default.
• W2055033467 creator A5019846161 @default.
• W2055033467 creator A5035870007 @default.
• W2055033467 creator A5036893121 @default.
• W2055033467 creator A5052240407 @default.
• W2055033467 creator A5060157317 @default.
• W2055033467 creator A5071143706 @default.
• W2055033467 creator A5088193611 @default.
• W2055033467 creator A5090608663 @default.
• W2055033467 date "2009-11-01" @default.
• W2055033467 modified "2023-10-01" @default.
• W2055033467 title "Hypofractionated Boost With High-Dose-Rate Brachytherapy and Open Magnetic Resonance Imaging–Guided Implants for Locally Aggressive Prostate Cancer: A Sequential Dose-Escalation Pilot Study" @default.
• W2055033467 cites W1496291651 @default.
• W2055033467 cites W1988909962 @default.
• W2055033467 cites W1990510898 @default.
• W2055033467 cites W1996809772 @default.
• W2055033467 cites W2001141099 @default.
• W2055033467 cites W2002386357 @default.
• W2055033467 cites W2006768292 @default.
• W2055033467 cites W2007269128 @default.
• W2055033467 cites W2015466920 @default.
• W2055033467 cites W2020594181 @default.
• W2055033467 cites W2042515254 @default.
• W2055033467 cites W2043945205 @default.
• W2055033467 cites W2045295764 @default.
• W2055033467 cites W2050744051 @default.
• W2055033467 cites W2056643793 @default.
• W2055033467 cites W2063266750 @default.
• W2055033467 cites W2065184437 @default.
• W2055033467 cites W2075346975 @default.
• W2055033467 cites W2079002624 @default.
• W2055033467 cites W2088893075 @default.
• W2055033467 cites W2089403922 @default.
• W2055033467 cites W2089983916 @default.
• W2055033467 cites W2093867637 @default.
• W2055033467 cites W2094599429 @default.
• W2055033467 cites W2121704058 @default.
• W2055033467 cites W2124537997 @default.
• W2055033467 cites W2130514725 @default.
• W2055033467 cites W2134460140 @default.
• W2055033467 cites W2135238404 @default.
• W2055033467 cites W2146145930 @default.
• W2055033467 cites W2149278436 @default.
• W2055033467 cites W2160406420 @default.
• W2055033467 cites W2163954169 @default.
• W2055033467 cites W4293241248 @default.
• W2055033467 doi "https://doi.org/10.1016/j.ijrobp.2008.11.023" @default.
• W2055033467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19250768" @default.
• W2055033467 hasPublicationYear "2009" @default.
• W2055033467 type Work @default.
• W2055033467 sameAs 2055033467 @default.
• W2055033467 citedByCount "51" @default.
• W2055033467 countsByYear W20550334672012 @default.
• W2055033467 countsByYear W20550334672013 @default.
• W2055033467 countsByYear W20550334672014 @default.
• W2055033467 countsByYear W20550334672015 @default.
• W2055033467 countsByYear W20550334672016 @default.
• W2055033467 countsByYear W20550334672017 @default.
• W2055033467 countsByYear W20550334672018 @default.
• W2055033467 countsByYear W20550334672020 @default.
• W2055033467 countsByYear W20550334672021 @default.
• W2055033467 countsByYear W20550334672022 @default.
• W2055033467 crossrefType "journal-article" @default.
• W2055033467 hasAuthorship W2055033467A5006149096 @default.
• W2055033467 hasAuthorship W2055033467A5015539696 @default.
• W2055033467 hasAuthorship W2055033467A5019846161 @default.
• W2055033467 hasAuthorship W2055033467A5035870007 @default.
• W2055033467 hasAuthorship W2055033467A5036893121 @default.
• W2055033467 hasAuthorship W2055033467A5052240407 @default.
• W2055033467 hasAuthorship W2055033467A5060157317 @default.
• W2055033467 hasAuthorship W2055033467A5071143706 @default.
• W2055033467 hasAuthorship W2055033467A5088193611 @default.
• W2055033467 hasAuthorship W2055033467A5090608663 @default.
• W2055033467 hasConcept C116263406 @default.
• W2055033467 hasConcept C121608353 @default.
• W2055033467 hasConcept C126322002 @default.
• W2055033467 hasConcept C126838900 @default.
• W2055033467 hasConcept C126894567 @default.
• W2055033467 hasConcept C143409427 @default.
• W2055033467 hasConcept C2776235491 @default.
• W2055033467 hasConcept C2777154038 @default.
• W2055033467 hasConcept C2777416452 @default.
• W2055033467 hasConcept C2777899217 @default.
• W2055033467 hasConcept C2778648096 @default.
• W2055033467 hasConcept C2780192828 @default.
• W2055033467 hasConcept C29730261 @default.
• W2055033467 hasConcept C2989005 @default.
• W2055033467 hasConcept C509974204 @default.
• W2055033467 hasConcept C71924100 @default.
• W2055033467 hasConceptScore W2055033467C116263406 @default.
• W2055033467 hasConceptScore W2055033467C121608353 @default.
• W2055033467 hasConceptScore W2055033467C126322002 @default.
• W2055033467 hasConceptScore W2055033467C126838900 @default.
• W2055033467 hasConceptScore W2055033467C126894567 @default.
• W2055033467 hasConceptScore W2055033467C143409427 @default.

• next